Palvella Therapeutics
PVLA
17 hedge funds and large institutions have $33.1M invested in Palvella Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.77% less ownership
Funds ownership: 44.49% → 43.72% (-0.77%)
6% less funds holding
Funds holding: 18 → 17 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
61% less capital inflows, than outflows
Capital inflows: $366K | Capital outflows: $937K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$176K |
| 2 |
DAFNA Capital Management
Los Angeles,
California
|
+$88.3K |
| 3 |
Oppenheimer & Co
New York
|
+$78.5K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$8.86K |
| 5 |
Walleye Trading
New York
|
+$5.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (USA)
New York
|
-$380K |
| 2 |
Millennium Management
New York
|
-$175K |
| 3 |
Emerald Advisers
Leola,
Pennsylvania
|
-$129K |
| 4 |
Spark Investment Management
New York
|
-$69K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$54K |
PVLA Hedge Fund Activity: Q1 2016 in Review
17 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2016, worth a combined $33.1M — down 18% from $40.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PVLA and 7 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, adding an estimated $176K. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $380K.
- 17 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2016, down from 18 in Q4 2015.
- Funds reported $33.1M of Palvella Therapeutics stock for Q1 2016, down 18% quarter-over-quarter.
- 7 funds opened new Palvella Therapeutics positions in Q1 2016 and 8 closed out, a net change of -1 holder.
- The largest Palvella Therapeutics buyer in Q1 2016 was Sabby Management, an estimated $176K added.
- The largest Palvella Therapeutics seller in Q1 2016 was Lombard Odier Asset Management (USA), an estimated $380K sold.
Based on aggregated 13F filings for Q1 2016.